Delcath Systems (DCTH) announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement to expand patient access. Delcath will participate in the Medicaid Drug Rebate Program, which entails providing Medicaid rebates and 340B discounts to eligible entities. The company has initiated the process of entering into the NDRA with the Centers for Medicare and Medicaid Services and expects it to take effect at the beginning of the third quarter of 2025. “Our decision to enter into the NDRA simplifies Medicaid access and enables eligible hospitals to access 340B drug pricing. We believe this will expand treatment availability and accelerate adoption of HEPZATO in the United States,” said Gerard Michel, CEO of Delcath. “Based on current center activation rates and rising utilization, we expect total HEPZATO treatment volume in 2025 to increase at least 200% versus 2024.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Shareholders Approve Key Amendments at Meeting
- Delcath Systems: Strong Revenue Growth and Strategic Expansion Drive Buy Rating
- Delcath Systems Reports Strong Q1 2025 Growth
- Delcath Systems’ Earnings Call Highlights Growth and Challenges
- Delcath Systems reports Q1 EPS 3c, consensus 3c